European Antibody Congress - Agenda Day 3

 

European Antibody Congress 2018, Day 3

08:00 Registration Opens

08:50 Conference doors open

World leading research

Chaired by Andreas Plückthun, Department of Biochemistry, University of Zurich

Prof. Andreas Plueckthun
09:05

An alternative strategy to generate binding proteins

    New concept for generating binding proteinsExploiting progress in protein design and crystallographyExploiting the modularity of targets
Frank Stenner
09:30

Antibodies against GOLPH2 for cancer therapy

  • GOLPH2 (GP73/GOLM1), a pro-oncogenic protein in a variety of cancers has hitherto been regarded to be undruggable
  • Novel antibodies with a unique mode of action target GOLPH2 positive tumors are to be presented
  • Preclinical data of these antibodies show high efficacy in vitro in EGFR- and KRAS-mutated cell lines
  • In vivo data of patient-derived xenografts confirm efficacy and indicate the way of further clinical development
Roland Kontermann
09:55

Bispecific and bifunctional fusion proteins

  • Concept of bispecific and bifunctional fusion proteins
  • Bispecific antibodies for dual targeting
  • Dual-acting costimulatory fusion proteins
  • Hexavalent death ligand fusion proteins

10:20 Networking refreshment break

Novel targets and biomarker discovery

Cutting-edge methods in antibody screening and immune repertoire sequencing

Computational antibody discovery and development

Research hub

Chaired by Jiri Kovarik, Research Investigator, Novartis

Chaired by Christoph Merten, Group Leader Microfluidics, European Molecular Biology Laboratory

Chaired by Anke Steinmetz, Senior Researcher, Integrated Drug Discovery, Sanofi Aventis R&D

Chaired by Andreas Hougaard Laustsen, Postdoctoral Fellow, Tropical Pharmacology Lab, Technical University of Denmark

Antibodies - Novel targets and biomarker discovery
11:20

Syngeneic system for a cell-based vaccination in rabbit

  • Antibody discovery in rabbit using a syngeneic cell-based vaccination
  • Large and diverse set of immortalized rabbit cells available with broad antigen expression capability
  • System well-suited to generate antibodies against complex membrane-bound antigens (transporter, GPCR)
  • Promising alternative to genetic or cross-species cell-based vaccination
Antibodies - Antibody screening and immune repertoire sequencing
11:20

Universal allosteric switch modules to regulate antibody affinities

  • Antibody affinities in FACS were regulated by a linker-based allosteric effector domain
  • Validated with 5 different svFv so far
  • Works both in VH-VL / VL-VH orientation
  • Regulation under physiological conditions (no ion concentration change)
Antibodies - Computational discovery and development
11:20

Experimental and computational profiling of Biologics: a powerful duo for next generation developability

  • Early lead selection of biotherapeutics during preclinical development requires careful characterization of a variety of molecule properties to reduce the risk for encountering unexpected obstacles during technical development
  • Developability assessment at Novartis combines information about expression, aggregation propensity, process fit, stability, solubility, physicochemical properties, in vivo fitness and immunogenicity of potential candidates
  • This integrated approach prior to lead selection provides a thorough, yet resource efficient approach
Antibodies - Research hub
11:20

Antibody discovery and engineering in mammalian cells by homology-directed mutagenesis

  • Optimizing conditions for homology-directed mutagenesis in mammalian cells
  • Designing, generating, and analyzing synthetic antibody libraries
  • Full-length antibody screening and affinity maturation in mammalian cells
  • Deep mutational scanning in mammalian cells by combining homology-directed mutagenesis and deep sequencing
Antibodies - Novel targets and biomarker discovery
11:40

Advanced antibody and assay capabilities to support target and biomarker validation and implementation

  • Robust antibody development, IP and regulatory management to deliver best-in-class antibodies, from research grade to IVD.
  • Abcam delivers true end-to-end solutions: from antibody discovery to assay development and commercialisation.
  • New FirePlex® platform for biomarker validation and implementation; robust detection from low sample input with exceptional performance and reproducibility.
Antibodies - Antibody screening and immune repertoire sequencing
11:40

Deep sequencing analysis of phage selection outputs: Leaving conventional screening behind

  • We will show adaptations to library design and panning strategies exploiting the full potential of deep sequencing analysis of phage selection output pools to identify high affine antibodies without conventional screening
Antibodies - Computational discovery and development
11:40

A computational framework for predicting protein liabilities & improvement of antibody developability

  • AggScore: a new method to identify aggregation hotspots on the interaction surface of proteins by evaluating hydrophobic, but also charged surface patches
  • BioQSPR: a machine-learning suite to generate prediction models to address issues like aggregation, solubility, stability and viscosity
Antibodies - Research hub
11:40

Targeting the inside of the cell with antibodies

  • Approaches to target the inside of the cell
  • Knockdown of various membrane receptors with intrabodies
  • Intrabody mediated knockdown in mice
Antibodies - Novel targets and biomarker discovery
12:00

Preclinical Development of ADCs against NSCLC

  • Antibody discovery via cell-based immunization
  • Phenotype-based drug screening approach to identify lead candidate
  • Characterisation and validation of antigen targets
  • Pre-clinical development of ADC in vitro and in vivo
Antibodies - Antibody screening and immune repertoire sequencing
12:00

Overcoming tolerance by deep mining of natural immune repertoires

  • Antibodies from natural immune responses are widely regarded as superior to those generated by display technologies
  • Immune tolerance poses a serious challenge for targets with high inter-species homology and Insoluble and poorly immunogenic targets such as membrane proteins exacerbate this challenge.
  • AbCellera’s ultra-deep screening technology overcomes these challenges, producing hundreds of diverse rodent antibodies against targets with 100% rodent-human homology, including G protein-coupled receptors
Antibodies - Computational discovery and development
12:00

Physical stability – structural homogeneity of biotherapeutic antibodies: property prediction by in silico methods

  • Discovery and development of biotherapeutic mAbs is a multiparametric optimization to balance biological and pharmaceutical properties such as stability
  • Stability refers to intricate structural, chemical, and physical processes. Methods for theoretical prediction of these processes generally focus on particular aspects, not on the global outcome of such modifications
  • We will report on a knowledge-based approach to predict aspects of stability by combining homology modelling, structural descriptor calculations, and classification algorithms
Antibodies - Research hub
12:00

Moving forward with adoptive transfer of expanded tumour-infiltrating lymphocytes (TIL) scientifically and in clinical practice

  • Determination of TIL quality and potential after initial harvesting
  • Effector phenotype of lymphocytes after excision and before infusion
  • Effect of serum and serum free medium on T lymphocytes
  • Timing and quantity of addition of antibodies to the TIL production
Antibodies - Novel targets and biomarker discovery
12:20

Thinking beyond antigen expression: SLC46A3 as a potential predictive biomarker for specific non-cleavable ADCs

  • While antibody-drug conjugates (ADCs) utilizing non-cleavable payloads have been approved for clinical use, and several are in development, predictive biomarkers beyond antigen expression are unknown.
  • We examined in vitro and patient-derived models of ADC resistance and found that loss of SLC46A3 expression is a mechanism of acquired and innate resistance to ADCs bearing the non-cleavable payloads DM1 and the pyrrolobenzodiazepine SG3376.
  • Expression of SLC46A3 may be more predictive of activity than target antigen levels alone
  • Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clinical trials involving these ADCs
Antibodies - Antibody screening and immune repertoire sequencing
12:20

Droplet-microfluidics in antibody discovery and immunoncology

  • New 2-cell platform enabling the screening of antibodies for their effect on target cells
  • Compatible with difficult targets such as GPCRs
  • Complementary platform for the stratification of cancer patients for personalized treatments
  • Results are available within 24h after surgery/biopsy at very competitive screening costs
Antibodies - Computational discovery and development
12:20

Computational and knowledge-based learning to optimise antibody design and engineering

  • Understanding the relationship between antibody structure and function
  • Engineering aspects in therapeutic antibody discovery and development
  • Computer-aided fully automated antibody humanization design
Antibodies - Research hub
12:20

Cytosolic delivery of DARPins by retargeted bacterial protein toxins

  • Crossing the cytoplasmic membrane remains the major hurdle in protein delivery
  • Cell-specific cytosolic delivery via toxin-inspired mechanism
  • Distinguishing intracellular from cytosolic localisation of delivered proteins
Antibodies - Novel targets and biomarker discovery
12:40

Towards a therapy of neurodegenerative diseases - a lesson learned from prion diseases

  • Neurodegenerative diseases
  • Prion diseases
  • Alzheimer's disease
  • Shed PrP, PrP226
  • Monoclonal antibody, scFv
  • BBB
  • Cell-penetrating peptide
Antibodies - Antibody screening and immune repertoire sequencing
12:40

MemoMAB: Antibody repertoires

  • Immune repertoire analysis and antibody discovery from human donors and animals
  • Repertoire biobanking in a screenable format using mammalian cell display
  • High fidelity and rapid turn-over times
Antibodies - Computational discovery and development
12:40

The sequence space of antibody repertoires

  • The sequence space that entire antibody repertoires cover is best investigated with large-scale networks
  • The sequence space architecture of antibody repertoires is reproducible, robust and redundant
  • Prospective on the predictability of evolutionary pathways in sequence space
Antibodies - Research hub
12:40

Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones

  • Introduction to disulfide rebridging as a strategy for the synthesis of homogenous bioconjugates
  • Introduction to dibromopyridazinediones as a conjugation reagent for disulfide rebridging
  • Exploring optimal conjugation conditions for achieving maximum homogeniety across multi-disulfide systems (especially IgG1 Abs)
  • Exploring the effect of disulfide rebridging on antibody activity, with focus towards Fc interactions

13:00 Networking Lunch

Closing Keynotes

Chaired by Alain Beck, Senior Director, NBEs Analytical Chemistry, Pierre Fabre, Associate Editor, mAbs

Paul Carter
14:00

Antibodies as drugs: Pursuit of the ‘high hanging fruit’

  • Opportunities and challenges with antibody drugs
  • Applications of bispecific antibodies
  • Efficient production of bispecific IgG in single host cells
Partha Chowdhury
14:25

Evolution and advancements in cancer immunotherapy

  • An accidental beginning and the lag phase
  • Checkpoint modulators and establishment of a new treatment paradigm: the growth phase
  • Understanding the pitfalls and road blocks: future efforts to escape the lag phase
Hélène Kaplon
14:50

Antibodies to watch in 2019

  • Brief Overview mAb therapeutics 1997-2017
  • Approvals in 2018
  • Antibodies to watch in 2019
15:25

Closing remarks from Terrapinn

15:30 - End of Congress

last published: 28/Oct/18 15:15 GMT

 

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.

 

Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October

Sign Up for Event Updates